SkinBioTherapeutics plc (LON:SBTX – Get Free Report) fell 1.7% during trading on Monday . The stock traded as low as GBX 16.50 ($0.21) and last traded at GBX 17.20 ($0.22). 759,267 shares traded hands during trading, an increase of 41% from the average session volume of 537,520 shares. The stock had previously closed at GBX 17.50 ($0.22).
SkinBioTherapeutics Price Performance
The business has a fifty day moving average of GBX 16.54 and a two-hundred day moving average of GBX 13.36. The firm has a market capitalization of £38.89 million, a price-to-earnings ratio of -860.00 and a beta of 2.01. The company has a debt-to-equity ratio of 2.66, a quick ratio of 10.01 and a current ratio of 6.57.
SkinBioTherapeutics Company Profile
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
Further Reading
- Five stocks we like better than SkinBioTherapeutics
- Investing in Travel Stocks Benefits
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- Top Stocks Investing in 5G Technology
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- What Are Treasury Bonds?
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
